Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT
-
Apr 14, 2026, 13:48Antoine Francis: This Is What a Donation Actually Becomes
-
Apr 14, 2026, 13:09Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
-
Apr 14, 2026, 13:01Shahzaib Maqbool: Preeclampsia Through a Hematology Lens
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster
-
Apr 14, 2026, 12:39Gonzalo Ladreda: Innovation in Stroke Care Is About Timing, Integration, and Real-World Usability
-
Apr 14, 2026, 12:30Roy P.C. Kessels: Stroke’s Cognitive Impact on Young Adults Is Significant and Often Overlooked
-
Apr 14, 2026, 12:22Mehari Gebreyohanns: New Insights on Wake-Up Strokes from Emergency Settings in Texas and Louisiana
-
Apr 14, 2026, 12:08Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026